Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL905580 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL9800685 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL9326087 | 1.00 | CSNK1E (0.50) | CSNK1EMMP1MMP9MMP13KCNH2 | |
| Ammonia Solution, Strong SCHEMBL297223 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL5826088 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL2948623 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL1784551 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL875995 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL5183320 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 | |
| Ammonia Solution, Strong SCHEMBL1840232 | 0.83 | CSNK1E (0.46) | CSNK1EMMP1MMP9MMP13CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | claimed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | claimed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | claimed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | claimed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | claimed |
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-9409951-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2016-08-09 | — | — | US | disclosed |
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
| US-8636977-B2 | Integrin targeted synthetic ligands for diagnostic and therapeutic applications | BRACCO IMAGING S.P.A. (IT) | 2014-01-28 | — | — | US | disclosed |
| WO-2012095516-A1 | HUMAN ANTIBODIES CROSS-REACTING WITH A BACTERIAL AND A SELF ANTIGEN FROM ATHEROSCLEROTIC PLAQUES | BRACCO IMAGING SPA (IT) | 2012-07-19 | — | — | WO | disclosed |
| EP-2320954-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | Bracco Imaging S.p.A (IT) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
| EP-2147684-A1 | Diagnostic Agents Selective Against Metalloproteases | Bracco Imaging S.p.A (IT) | 2010-01-27 | — | — | EP | disclosed |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | BRACCO IMAGING S.P.A. (IT) | 2008-12-25 | — | — | US | disclosed |
| EP-1853605-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | Bracco Imaging, S.P.A. (IT) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006095234-A2 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2006-09-14 | — | — | WO | disclosed |
| US-5075159-A | Binding polyfunctional epoxy resin, impregnation bifunctional epoxy resin | KOYAMA TOHRU (JP) | 1991-12-24 | — | — | US | disclosed |
| EP-0413179-A2 | Electrically insulated coil, electric rotating machine, and method of manufacturing same | HITACHI, LTD. (JP) | 1991-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP1 3220/4885MMP9 2086/4885 |
| US-20080317668-A1 | Integrin Targeted Synthetic Ligands for Diagnostic and Therapeutic Applications | ITGA2B, ITGB2, ITGB1 | CSNK1E 1023/4885MMP1 3220/4885MMP9 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.